KBI Biopharma Inc.

Celltrion continues to establish its frontrunner position in the omalizumab biosimilar race as the firm submits a biologic license application to the US Food and Drug Administration for its CT-P39, a

Selexis and Generium have announced the launch of their Genolar (omalizumab) biosimilar in Russia, with the rival to the Xolair asthma and urticaria treatment marking the pair’s third biosimilar to

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Amgen, Plexium Team Up Against Challeng

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held